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A B S T R A C T
Gas chromatography (GC) hyphenated with nitrogen chemiluminescence detection (NCD) and
quadrupole time-of-ﬂight mass spectrometry (QTOFMS) was applied for the ﬁrst time to the quantitative
analysis of new psychoactive substances (NPS) in urine, based on the N-equimolar response of NCD. A
method was developed and validated to estimate the concentrations of three metabolites of the common
stimulant NPS a-pyrrolidinovalerophenone (a-PVP) in spiked urine samples, simulating an analysis
having no authentic reference standards for the metabolites and using the parent drug instead for
quantitative calibration. The metabolites studied were OH-a-PVP (M1), 200-oxo-a-PVP (M3), and N,N-bis-
dealkyl-PVP (2-amino-1-phenylpentan-1-one; M5). Sample preparation involved liquid–liquid extrac-
tion with a mixture of ethyl acetate and butyl chloride at a basic pH and subsequent silylation of the sec-
hydroxyl and prim-amino groups of M1 and M5, respectively. Simultaneous compound identiﬁcation was
based on the accurate masses of the protonated molecules for each compound by QTOFMS following
atmospheric pressure chemical ionization. The accuracy of quantiﬁcation of the parent-calibrated NCD
method was compared with that of the corresponding parent-calibrated QTOFMS method, as well as with
a reference QTOFMS method calibrated with the authentic reference standards. The NCD method
produced an equally good accuracy to the reference method for a-PVP, M3 and M5, while a higher
negative bias (25%) was obtained for M1, best explainable by recovery and stability issues. The
performance of the parent-calibrated QTOFMS method was inferior to the reference method with an
especially high negative bias (60%) for M1. The NCD method enabled better quantitative precision than
the QTOFMS methods To evaluate the novel approach in casework, twenty post- mortem urine samples
previously found positive for a-PVP were analyzed by the parent calibrated NCD method and the
reference QTOFMS method. The highest difference in the quantitative results between the two methods
was only 33%, and the NCD method’s precision as the coefﬁcient of variation was better than 13%. The
limit of quantiﬁcation for the NCD method was approximately 0.25 mg/mL in urine, which generally
allowed the analysis of a-PVP and the main metabolite M1. However, the sensitivity was not sufﬁcient for
the low concentrations of M3 and M5. Consequently, while having potential for instant analysis of NPS
and metabolites in moderate concentrations without reference standards, the NCD method should be
further developed for improved sensitivity to be more generally applicable.
© 2018 Elsevier B.V. All rights reserved.
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The continuous emergence of new psychoactive substances (NPS)
poseachallengeforbothtoxicologicalanalysisandcaseinterpretation.
Among the hundreds of NPS recognized during the ten previous years,* Corresponding author at: University of Helsinki, Department of Forensic
Medicine, P.O. Box 40, FI-00014 University of Helsinki, Finland.
E-mail address: samuel.mesihaa@helsinki.ﬁ (S. Mesihää).
https://doi.org/10.1016/j.forsciint.2018.02.017
0379-0738/© 2018 Elsevier B.V. All rights reserved.the stimulant alpha-pyrrolidinovalerophenone (a-PVP) has turned
out tobeoneof themoreestablisheddrugson the illicitmarketdespite
scheduling as a controlled substance in many countries. a-PVP
belongs to the “second generation” cathinones that appeared on the
illicit market in Europe in 2011 following the “ﬁrst generation”
cathinones 3,4-methylenedioxypyrovalerone (MDPV), 3,4-methyle-
nedioxymethcathinone (methylone), and 4-methylmethcathinone
(mephedrone). Current studies suggest that the potency of cathinones
to reinforce responding in animal studies, and consequently increased
Fig. 1. Chemical structures, molecular formulas and accurate masses of the
protonated molecules of a-pyrrolidinovalerophenone (a-PVP) and three of its
metabolites (M1, M3, M5).
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[1]. a-PVP has more dopaminergic than serotonergic properties
compared with amphetamine analogues [2]. The Risk Assessment
carried out by the European Monitoring Centre for Drugs and Drug
Addiction reported 116 deaths associated with a-PVP between 2012
and 2015 in eight member states [3]. Recently, Swedish authors
published a case series of consecutive patients within the STRIDA
project with admitted or suspected intake of NPS presenting to
hospitals for emergency treatment from January 2011 to March 2016.
They detected 45 a-PVP and 17 MDPV cases in addition to 114
intoxications involving any of 11 other pyrovalerone drugs [4].
Qualitative screening for a broad range of NPS in biological
samples is feasible by modern analytical techniques, notably taking
advance of the speciﬁcity and ﬂexibility of high-resolution mass
spectrometry. Accurate mass-based identiﬁcation of NPS in data-
independent acquisition mode is particularly useful since it enables
immediate suspect screening, while subsequent conﬁrmation can be
accomplished once a reference standard has been obtained [5].
However, quantiﬁcation still remains a major challenge. Continuous
appearance and disappearance of NPS complicates the acquisition of
authentic reference standards because the standards are expensive
and difﬁcult to obtain in a sufﬁciently short period of time.
Metabolites of NPS are rarely commercially available, and conse-
quently expensive custom syntheses may be required to include the
most important metabolites in the analysis panel.
It is well recognized that the present-day routine analytical
method, liquid chromatography electrospray triple quadrupole
tandem mass spectrometry (LC-ESI-MS/MS), is at best suitable only
for semi-quantitative estimation of metabolite concentrations when
using the parent drug forcalibration, because of the large variation in
responses between the compounds [6]. However, there are non-MS
techniques available that provide a more universal response [7,8].
Nitrogen chemiluminescence detection (NCD) shows equimolar
response to nitrogen that could be exploited in universal quantiﬁca-
tion of nitrogen containing compounds [9]. In our previous studies
[10,11], we introduced a novel platform for simultaneous identiﬁca-
tion and quantiﬁcation of NPS in the absence of authentic reference
standards. The instrumentation consisted of gas chromatography
(GC) coupled to NCD and atmospheric pressure chemical ionization
quadrupole time-of-ﬂight mass spectrometry (APCI-QTOFMS). The
GC ﬂow was divided in appropriate proportions between NCD and
QTOFMS to achieve quantiﬁcation and identiﬁcation, respectively.
We obtained promising quantitative results by analyzing blood
samples that were spiked post-extraction to avoid emphasizing
recovery issues [10]. In addition, we were able to show that taking
advantage of the accurate mass measurement of the protonated
molecule and product ions by GC-APCI-QTOFMS, the obtained MS/
MS spectra were comparable to existing soft-ionization mass
spectral libraries [11].
In the present study, our objective was to advance the concept
further by developing a quantitative analysis method, based on the
GC-NCD-APCI-QTOFMS platform, for a-PVP and its three metab-
olites in urine samples using the parent drug for calibration.
Following liquid–liquid extraction, a derivatization step was
introduced to avoid undesirable adsorption of polar metabolites
in the GC inlet and column [12,13]. Thereafter, post-mortem urine
samples previously found positive for a-PVP were re-analyzed by
the developed method to reveal the metabolite concentrations.
2. Materials and methods
2.1. Chemicals
a-PVP and the N,N-bis-dealkyl-PVP (2-amino-1-phenylpentan-
1-one; M5) were from Chiron AS (Trondheim, Norway), OH-a-PVP
(M1) was from Cayman Chemical (Ann Arbor, MI, USA), and 200-Oxo-a-PVP (M3) from Toronto Research Chemicals (Toronto, ON,
Canada). The structures of a-PVP and the three metabolites used in
the study are shown in Fig. 1. The derivatization agent MSTFA (N-
methyl-N-trimethylsilyltriﬂuoroacetamide) with 1% TMCS (2,2,2-
triﬂuoro-N-methyl-N-(trimethylsilyl)-acetamide, chlorotrimethyl-
silane) was from Thermo Fisher Scientiﬁc (Bellefonte, PA, USA).
2.2. Sample preparation
Blank urine samples from ﬁve healthy volunteers were used for
the validation experiments. The blank urines did not contain co-
eluting nitrogen-containing components that would interfere with
quantiﬁcation at NCD. Blank urine aliquots were spiked to create
external calibration curves for MS and NCD quantiﬁcations. Each
reference standard was dissolved in methanol to obtain a 1 mg/mL
stock solution. The stock solution was diluted to obtain a working
solution containing a mixture of a-PVP and metabolites M1, M3
and M5 within a concentration range of 0.4–200 mg/mL. Blank
urine (1 mL) was spiked with 25 mL of the working solution to
prepare solutions ranging from 0.01 to 5 mg/mL.
Twenty post-mortem urine samples from medico-legal autop-
sies, previously identiﬁed as positive for a-PVP, were selected for
metabolite quantiﬁcation. In such samples where the analytes
caused a signal saturation to the mass selective detector the urine
volume was adjusted to match 0.2–1 mg/mL concentration.
The pH of the urine samples was adjusted by mixing with
400 mL of 1 M Tris buffer (pH 11) and 40 mL of 1 M NaOH in a 6-mL
centrifuge tube, resulting in a pH between 10–12. The mixture was
extracted with 500 mL of ethyl acetate + butyl chloride (75 + 25) in a
vortex mixer for 2 min. After centrifugation, an aliquot (100 mL) of
the organic phase was transferred into a conical autosampler vial.
For the derivatization procedure, the organic phase was mixed
with 40 mL of MSTFA + 1% TMCS silylation reagent, incubated for
15 min at 50 C and mixed prior to GC injection.
2.3. Instrumentation
A 7890B Series GC System equipped with a 7693 Automatic
Liquid Sampler and a split/splitless injector was coupled through a
two-way splitter with makeup gas (He) to an Agilent 6540 UHD
Accurate-Mass QTOF mass analyser and a 255 Nitrogen Chemilu-
minescence Detector (all Agilent Technologies, Santa Clara, CA,
USA).
2.4. Nitrogen chemiluminescence detection
Pyrolysis of the analytes at NCD was carried out at 900 C using
a hydrogen ﬂow rate of 4 mL/min and an oxygen ﬂow rate of
9.4 mL/min. Data from NCD was collected at 50 Hz over the entire
course of the analysis. OpenLab CDS Chemstation GC driver
A.02.05.021 was used to control GC-NCD.
Table 1
Accuracy of quantiﬁcation of parent drug-calibrated NCD method, parent drug-calibrated QTOFMS method and reference QTOFMS method calibrated with authentic
reference standards.a
Spiked concentration (mg/mL) Measured concentration (mg/mL) CV (%) Bias (%)
GC-NCD calibrated with a-PVP
a-PVP 0.25 0.26 8 4
1.00 0.94 4 6
M1 0.25 0.19 13 24
1.00 0.75 7 25
M3 0.25 0.27 8 8
1.00 1.09 5 9
M5 0.25 0.29 8 16
1.00 1.05 5 5
GC-APCI-QTOFMS calibrated with a-PVP
a-PVP 0.25 0.22 18 12
1.00 1.03 12 3
M1 0.25 0.10 12 60
1.00 0.42 15 58
M3 0.25 0.24 13 4
1.00 1.09 14 9
M5 0.25 0.18 12 28
1.00 0.83 11 17
GC-APCI-QTOFMS calibrated with authentic reference standards
a-PVP 0.25 0.22 18 12
1.00 1.03 12 3
M1 0.25 0.25 12 0
1.00 1.00 15 0
M3 0.25 0.22 13 12
1.00 1.00 14 0
M5 0.25 0.21 12 16
1.00 0.94 11 6
a Averaged values from ﬁve different urine samples, each measured in duplicate in six separate days.
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sequence, using the equimolar nitrogen response to a-PVP. Three
calibration points (0.25, 1 and 5 mg/mL) were measured in spiked
blank urine samples after extraction and derivatization.
The amount of nitrogen was calculated by multiplying the
relative amount of nitrogen in the molecule by concentration,
dilution factor caused by the derivatization reagent, and injection
volume.
2.5. Gas chromatography
Injector liner was a Single taper Ultra Inert liner with glass wool
(Agilent 5190-2293). Analytical column was a DB-5MS (30 m
 0.25 mm id with 0.1 mm ﬁlm) capillary column (Agilent
Technologies). After the analytical column, the GC ﬂow was
divided between the NCD and the APCI ion source through a two-
way splitter, using 0.55 m  0.18 mm and 2 m  0.18 mm uncoated
deactivated fused-silica post-columns to obtain a 10:1 ﬂow ratio,
respectively. The splitter pressure was 15.8 psi and the ﬂow ratio
was calculated using the Efﬂuent Splitter Calculator (with Makeup)
(Agilent Technologies). In this concurrent detection, the NCD signal
is detected 0.02 min earlier than QTOFMS.
GC was operated in the pulsed splitless injection mode with an
equilibration time of 0.75 min and 50 mL/min purge ﬂow to split
vent at 0.75 min. A pulse pressure of 50 psi for 0.75 min was applied
prior to using initial head pressure of 24.9 psi. The injector port
temperature was 250 C and the transfer line temperature 320 C.
The injection volume was 1.0 mL. The oven temperature was
initially held at 100 C for 0.75 min and then increased by 30 C per
min to 320 C, which was held for 6 min. Helium was used as carrier
gas at 1 mL/min in the constant ﬂow mode.2.6. Mass spectrometry
QTOFMS was operated in APCI positive ionization mode, drying
gas (nitrogen) ﬂow at 5.0 L/min and gas temperature at 365 C.
Corona discharge needle current was 1000 nA and capillary voltage
1000 V. Fragmentor voltage was 140 V and skimmer voltage 65 V.
Mass acquisition was performed in All-ions mode, and data
were recorded over the m/z range of 50–400 with an acquisition
rate of 5 spectra/s. Collision energy in the low energy function was
0 eV, whereas in the high energy function 10 and 20 eV were used.
External mass calibration was carried out using the APCI tuning
mix (Agilent Technologies). Ion m/z 257.2475 was used for internal
calibration throughout the chromatographic separation. QTOFMS
was operated in 2 GHz, Extended Dynamic Range mode.
All data were collected with MassHunter Data Acquisition
B.04.00 software (Agilent Technologies). MassHunter Proﬁnder
B.06.00 software (Agilent Technologies) was used for initial data
processing and compound identiﬁcation.
2.7. Validation
Validation was performed according to the recommended
guidelines [14], where appropriate. Limit of detection (LOD) was
determined using the following criteria for tentative identiﬁcation:
peak area of >1000, retention time tolerance of 0.1 min, and mass
tolerance of 1 mDa. All the quantitative data, including the limit of
quantiﬁcation (LOQ), bias, and precision, were gathered from
parallel measurements of ﬁve calibration points ranging from 0.01
to 1 mg/mL in spiked control urine samples (Tables 1 and 2).
Processed sample stability at room temperature at concentrations
of 0.01 and 1.0 mg/mL was tested by measuring the difference from
Table 2
GC-NCD-APCI-QTOFMS method validation results for a-PVP, M1, M3 and M5.
Parameter Detector Acceptance criteria Result
Bias NCD 30% Range from 25 to 16%a
Carryover QTOFMS <10% of LOD No carryover at 10 mg/mLb
LOD QTOFMS Identiﬁcation criteria must be met 10 ng/mL
LOQ NCD Bias and precision criteria must be met 16 pg/N/injectionc, CV < 13%
Precision NCD CV  20% Range from 4 to 13%a
Processed sample
stability
QTOFMS 20% compared to to > 10 hd
Selectivity NCD No signiﬁcant peak overlapping 9/80 (11%) of results by NCD and/or QTOFMS were
disqualiﬁed
QTOFMS Full scan mode: Area of [M+H]+at apex must be >5-fold from all other
peaks
a Averaged values from ﬁve different urine samples, each measured in duplicate in six separate days.
b Averaged values from ﬁve different urine samples measured in triplicate.
c Corresponding to approximately 0.25 mg/mL of derivatized M1.
d Averaged values from one urine sample, measured in triplicate in one hour intervals for 10 h.
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Selectivity was measured from actual post-mortem samples.
3. Results & discussion
3.1. Method validation with spiked urine samples
A quantitative analysis method by GC-NCD-APCI-QTOFMS was
developed for a-PVP and its metabolites M1, M3 and M5 in urine
samples. Liquid–liquid extraction was chosen because the tech-
nique is rather non-selective and easy to master. Among the
several extraction solvents tested, a mixture of ethyl acetate and
butyl chloride (75 + 25) at a basic pH was found to produce a
sufﬁciently uniform extraction recovery for all the study com-
pounds without excessive background noise.
The sec-hydroxyl- (M1) and prim-amino (M5) metabolites
showed initially adsorption and unsymmetrical peaks in GC, and
consequently a derivatization step with MSTFA to form trime-
thylsilyl (TMS) derivatives was included. Compound identiﬁcation
was based on the accurate masses of the protonated molecules for
each compound by GC-APCI-QTOFMS. For M1 and M5 the addition
of the TMS moiety resulted in a mass shift of +72.0396 Da to the
protonated molecule. Fig. 2 shows a GC-NCD chromatogram from
spiked urine samples containing a-PVP and metabolites M1, M3
and M5 at two concentration levels.
An experimental setting was designed that simulated a
quantitative analysis having no authentic reference standardsFig. 2. GC-NCD chromatogram from spiked urine samples containing 0.25 mg/mL (blue)
the references to colour in this ﬁgure legend, the reader is referred to the web versionfor the metabolites and using the parent drug instead for
quantitative calibration, assuming that the extraction recovery
of the parent drug equals that of the metabolites.
Table 1 shows the accuracy of quantiﬁcation of the parent-
calibrated NCD method, compared with that of the corresponding
parent-calibratedQTOFMSmethod and a reference QTOFMS method
calibrated with the authentic reference standards. The NCD method
produced generally a better quantitative precision than the QTOFMS
methods. The NCD method showed an equally good accuracy to the
reference method for a-PVP, M3 and M5, but a higher negative bias
(24–25%) was obtained for M1. The bias was due to a combined effect
of lower extraction recovery and relative instability of the TMS
derivative of M1. Cleavage of the TMS derivative was veriﬁed as an
increase of free M1 with time, and consequently it is recommended
to minimize the storage time of the prepared samples prior to
analysis. The parent-calibrated QTOFMS method performed worse
than the reference method with an especially high negative bias (58–
60%) for M1. This result is obviously due to the differences in the
ionization efﬁciency in the APCI source, in addition to the lower
extraction recovery and instability issues.
Acceptance criteria for all method validation parameters
determined are summarized in Table 2.
At NCD all compounds are pyrolyzed prior to the chemilumi-
nescent detection. This ensures that the response of most nitrogen-
containing compounds is equimolar regardless of the molecular
structure or condition, with a notable exception of adjacent
nitrogen atoms as pointed out by Yan [9]. The fact that neither of and 1 mg/mL (red) of a-PVP and metabolites M1, M3 and M5. (For interpretation of
 of this article.)
Table 3
Comparison of measured drug concentrations in twenty post-mortem urine
samples between GC-APCI-QTOFMS calibrated with authentic reference standards
and GC-NCD calibrated with a-PVP.
Sample a-PVP (mg/mL) M1 (mg/mL) M3 (mg/mL) M5 (mg/mL)
MS NCD MS NCD MS NCD MS NCD
1a 8.52 8.04 6.77 5.18 0.21 b 0.05 c
2a 4.64 5.16 4.23 3.05 0.52 b 0.10 c
3a 3.03 3.01 0.97 0.71 0.35 0.38 <0.01 c
4a 2.93 3.01 3.66 2.92 0.63 0.70 0.06 c
5a 2.04 1.56 1.66 1.14 0.24 b 0.04 c
6a 1.25 1.51 1.53 1.06 0.27 b 0.03 c
7a 1.16 1.41 0.57 0.48 0.13 c 0.01 c
8 0.99 1.20 1.47 1.00 0.05 c 0.03 c
9 0.80 0.82 0.33 b 0.08 c 0.01 c
10 0.74 0.72 0.69 0.46 0.05 c <0.01 c
11 0.58 0.58 0.35 0.27 0.04 c <0.01 c
12 0.37 b 0.27 0.18 0.19 b 0.01 c
13 0.25 0.30 0.29 b 0.03 c 0.01 c
14 0.13 c 0.05 c 0.01 c ND c
15 0.10 c 0.05 c <0.01 c ND c
16 0.09 c 0.14 c 0.01 c <0.01 c
17 0.05 c 0.02 c <0.01 c <0.01 c
18 0.05 c 0.02 c <0.01 c <0.01 c
19 0.02 c 0.03 c ND c ND c
20 0.02 c 0.57 b 0.01 c <0.01 c
Average bias (%)d 5.8 26.9 9.9
CV (%)e 12 13 17 8 17 2 18
a A smaller volume of urine was used to avoid signal saturation at GC-QTOFMS.
b Matrix interference in NCD chromatogram.
c Value below LOQ.
d Average bias (%) was calculated by comparing MS and NCD measurements.
e CV (%) was calculated from duplicate measurements.
Fig. 3. Interfering compounds in post-mortem urine #7. (A) In NCD chromatogram co-elu
TMS derivatized peak of protonated M5 (m/z 250.1622) contributes only minimally to 
16 S. Mesihää et al. / Forensic Science International 286 (2018) 12–17the parent-calibrated methods was capable of fully compensating
the extraction recovery of M1 emphasizes the importance of
developing a sample preparation method as generic as possible.
However, acceptable levels of accuracy were reached using the
parent-calibrated NCD method contrary to the parent-calibrated
QTOFMS method. Indeed, quantiﬁcation of metabolites by MS in
the absence of authentic reference standards is at best only semi-
quantitative. A study by Hatsis et al. [6] found up to a 70-fold
difference in ion response factor between metabolite and parent
drug by ESI-LC-MS/MS.
3.2. Investigation of post-mortem urine samples
To evaluate the novel GC-NCD-APCI-QTOFMS platform in
casework, twenty post-mortem urine samples previously found
positive for a-PVP were analyzed by the parent-calibrated NCD
method and the reference QTOFMS method. Table 3 shows that by
using the parent-calibrated NCD method a quantitative result was
obtained in 12 out of 20, 11/20, 2/20 and 0/20 cases for a-PVP, M1,
M3 and M5, respectively. The highest difference in the quantitative
results between the two methods was only 33%, and the NCD
method’s precision expressed as the coefﬁcient of variation was
better than 13%. The accuracy and precision of quantiﬁcation for
post-mortem samples was similar to that for the spiked urine
samples by the parent-calibrated NCD method (Table 3).
M1 and M3 have been considered as the major metabolites of
a-PVP in humans [15]. In our cases, the presence of these
metabolites was conﬁrmed in all but one urine sample by GC-APCI-
QTOFMS. Currently, the sensitivity of NCD was not sufﬁcient to
quantify all metabolites, especially the minor metabolite M5.
Moreover, interference caused by co-eluting nitrogen compoundsting compounds result in overestimation of M5. (B) QTOFMS spectrum conﬁrms that
total NCD peak area.
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metabolite concentrations (Fig. 3).
According to the manufacturer, the NCD detector can detect
nitrogen over the carbon background signal in the mass ratio of 107
to one. However, co-eluting nitrogen-containing compounds can
cause overestimation in NCD quantiﬁcation. Such compounds can
be due to a multidrug intake or they can be common endogenous
urine compounds which are prevalent at low concentrations. In
Table 2 we have set criteria for assessing the quality of the
quantitative data. For high-sensitivity NCD analysis, common
matrix background peaks should be subtracted using a blank urine.
A viable strategy to enhance chromatographic selectivity would be
using two-dimensional GC [16].
4. Conclusions
This studydemonstrated that the currentGC-NCD-APCI-QTOFMS
instrument platform has potential in the rapid quantitative
bioanalysis of the main a-PVP metabolites together with the parent
drug in cases where authentic reference standards are not
immediately available. As conventional validated analysis neces-
sitates information on retention time, compound speciﬁc spectral
fragmentation and quantitative response obtained with an authentic
reference standard, these conditions cannot be realized in case of
infrequently encountered NPS metabolites. However, identifying
NPS metabolites would facilitate the conﬁrmation of the parent
drugs, and metabolite quantiﬁcation can aid forensic interpretation,
in particular when investigating the time of drug intake utilizing
metabolite to parent drug ratios. In future studies we will seek to
improve the NCD method’s LOQ using the large volume injection and
widen the scope of substances included in the NPS screening.
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